Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pimethixene
- Development stage
- Unknown
- Lead developer
- Laboratoires Salvoxyl
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pimethixene is a small molecule drug of the thioxanthene class with antihistamine and anticholinergic properties. It acts as an antagonist at histamine H1 receptor and muscarinic acetylcholine M2 receptor, and also displays high affinity for serotonin 5-HT2A and 5-HT2B receptors. Pimethixene was originally developed to treat hyperactivity, anxiety, sleep disorders, allergies, and has been used as a sedative agent in anesthesia as well as a bronchodilator. It is approved for use in Brazil (Muricalm) primarily for the treatment of bronchitis and dry cough in children older than two years. In France it was previously marketed in combination with pholcodine under the name Salvodex[1][2][3][4][6].
- Brand names
- MuricalmCalmixeneSalvodex
- Other names
- mepithiathenecalmixene314-03-4
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD4 (Dopamine D4 Receptor)M1 (Muscarinic acetylcholine receptor M1)HTR2A (Serotonin receptor 5-HT2A)CHRM2 (M2)DRD2 (Dopamine D2 Receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on pimethixene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pimethixene.